AzTrials
AzTrials

Morbid ObesityNCT01063127

A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity

An observational study of Morbid Obesity, run by Catholic University of the Sacred Heart at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to quantify the relative contribution of improved insulin sensitivity and improved insulin secretion to the glycaemic effect of bariatric surgery. Read more about this study

Who is it for?
Ages 25 to 55 years
Conditions the study is for
Morbid Obesity
What is being tested?
Study on insulin sensitivity after diet or bariatric surgery and gastric bypass
How many people
23 participants
Where
1 siteItaly
Study dates
Feb 2010to Jul 2012
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: Twenty morbidly obese subjects scheduled for RYGB or LAGB for will be included in the study.

Who may be able to join

  • Morbidly obese subjects of both sexes with a BMI >40 kg/m2 who, for their obesity disease, are eligible for bariatric surgery and have accepted to undergo RYGB or LAGB
  • Confirmed insulin resistance as assessed by Matsuda index
  • Age 25-55 years
  • Weight stable for at least 6 months before the study (+/- 5 kg within the previous 6 months)
  • Stable medication
  • Provision of informed consent, statistical analysis, and publications of obtained results

Who cannot join

  • Patients not eligible for laparoscopic RYGB or LAGB
  • Incapacity to give a valid informed consent or unwilling to give the consent
  • Pregnancy or lactating
  • Patients eligible for RYGB/LAGB, but with:
  • Type 2-diabetes mellitus
  • Significant illness within the two weeks preceding surgery, as judged by the physician.
  • Obvious infection (bacteria, virus etc)
  • Major cardiovascular disease

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Department of Internal Medicine, Catholic University

    Rome, 00168

Other trials in Italy

About this study

Official title: A Longitudinal, Open-label Study on the Short-term Effects of Roux-en-Y Gastric Bypass Surgery vs. Gastric Banding on Glucose Homeostasis in Obese Subjects

The purpose of this study is to quantify the relative contribution of improved insulin sensitivity and improved insulin secretion to the glycaemic effect of bariatric surgery.

Read the detailed description

In 1987 Pories et al. (1) published that after gastric bypass 99% of morbidly obese patients became and remained euglycaemic over time. However, the most interesting observation of these authors (1) was that the patients were converted to euglycaemia within 10 days of the operation, even if before they required large doses of insulin. Thereafter, we ourselves (2-6) as well as other Authors (7,8) have found that both mainly malabsorptive bariatric and mainly restrictive surgery are effective in producing early improvement/resolution of type 2 diabetes, also in normal weight (9) or overweight-obese subjects (10).

Until now the mechanisms through which bariatric surgery operate in improving insulin sensitivity and, consequently, diabetes control have not been elucidated. To complicate the picture there is the fact that after bariatric surgery patients are not allowed to eat for a time that is longer as the entity of the abdominal trauma increases. In fact, after laparoscopic bariatric surgery the patients are re-alimented in the 3rd post-operative day while after open surgery the time length before re-alimentation is about 7 days. Although in most centres the patients receive a parenteral nutrition covering the energy needs while they remain at rest, in some other centres they are only re-hydrated. Thus, it might be hypothesised that fasting can contribute to the improvement of glucose disposal. The data in the literature counteract this possibility as many Authors (11-15) have demonstrated that a very-low calorie diet (VLCD) is essentially unable to improve insulin sensitivity at least in the short run, when the weight loss is minimal. In this regard, Jazet et al. (11) found that the glucose control amelioration in diabetic subjects undergoing a 2-day VLCD was a reduction in the hepatic glucose production rather than an improvement in the whole-body glucose disposal. Similarly, Christiansen et al (12) observed the increase in the glucose metabolic clearance rate (MCR) was not apparent before day 20 of energy restriction, when the weight loss became significant. In another study, diabetic patients under a 4-day energy-restricted diet (providing 4620 ± 1050 kJ/d) had a deterioration of both basal glucose MCR and insulin-stimulated glucose disposal (13).

Recently, Laferrère et al (16) compared the late (1 month) effect of an equivalent weight loss by RYGB or by diet in two groups of matched morbidly obese patients with type 2 diabetes mellitus. The glucose area under-the-curve (AUC) after an oral glucose tolerance test (OGTT) and glucose levels at 120' were significantly lower after RYGB compared with diet (P = 0.014 and P = 0.001, respectively).

Another important aspect of the weight loss is the modulation of lipolysis. Many studies have shown that obese subjects are insulin resistant at the level of adipose tissue, ie, despite high plasma insulin levels lipolysis and FFA release are not suppressed. It is therefore interesting to study the changes in lipolysis before and after surgery and also the ability of insulin (e.g., during the euglycemic, hyperinsulinemic clamp) to suppress peripheral lipolysis. By infusing deuterated glycerol we will be able to estimate glycerol rate of appearance, which is the best available index of lipolysis. In fact intracellular triglyceride (TG) hydrolysis results in the release of one mole of glycerol and 3 moles of FFA. While the FFA can be re-esterified intracellularly, and thus do not appear into the systemic circulation, glycerol cannot be re-esterified since the adipocyte lacks glycerol kinase. Thus, all glycerol derived from intracellular TG hydrolysis is released into the circulation and can be traced by deuterated glycerol. We have used this technique previously in diabetic subjects (17), in subjects with NASH as well as in obese subjects under VLCD (18). In the latter study we have shown that VLCD improved adipose tissue IR.

As far as we know, no data are available in the literature comparing the effect of RYGB with a purely restrictive bariatric procedure in order to take into account simultaneously the effect of the surgical trauma and that of the reduced food intake in the early post-operative period.

The main goal of this study is to determine the immediate effect of Roux-en-Y gastric bypass surgery on glucose homeostasis, factoring out the confounding effects of the surgical approach (incl. laparoscopy) and of the post-operative fasting.

To this purpose, patients of the two bariatric surgery groups (Roux-en-Y gastric bypass and gastric banding) are matched as far as feasible. Primary parameter is insulin resistance (as assessed by Matsuda index). Further the same BMI inclusion criteria apply for both groups (BMI > 30 kg/m2 and < 55 kg/m2). While age, gender and BMI within the specified range are also expected to influence the read-outs, no matching for these baseline characteristics is foreseen due to feasibility issues.

Patients receive oral food typically from day 3 or 4 after laparoscopic bariatric surgery. This post-operative food intake is restricted to 800 - 1000 kcal/day, usually divided in 6 small meals, with the following composition 55% carbohydrates, 30% lipids and 15% proteins; saturated lipids ~ 10% . A similar caloric intake restriction will be imposed during the 1-week diet period prior to Visit 3, which will be done 10 +/- 2 weeks before the operation in order to allow the patients a complete recovery of his/her body weight which must be kept constant before the next study in order to avoid methodological biases.

Conditions
Morbid Obesity
Being tested
Study on insulin sensitivity after diet or bariatric surgery, gastric bypass
Keywords
Morbid obesity, Insulin resistance, Euglycemic clamp
Medical subject headings
Obesity, Morbid, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Study on insulin sensitivity after diet or bariatric surgeryOther

    Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass

  • gastric bypassOther

    Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass

Study groups in NCT01063127
Study groupRoleWhat they receive
1group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
2group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
Receives: Other: Study on insulin sensitivity after diet or bariatric surgery; Other: gastric bypass

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Insulin sensibility pre and post bariatric surgery with euglycaemic hyperinsulinemic clamp (EHC)

    Measured: 12 and 11 weeks before surgery and 1 week after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2010 (estimated)
  2. Study startFeb 2010
  3. Primary completionDec 2011
  4. Study completionJul 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
23 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01063127
Sponsor's protocol ID
749/09
Status last verified
Feb 2013
First submitted
26 Jan 2010
Last updated
15 Feb 2013
Results posted
No
Data monitoring committee
No

Publications

  • Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006 Jul;55(7):2025-31. doi: 10.2337/db06-0068.

    PubMed 16804072
  • Salinari S, Bertuzzi A, Iaconelli A, Manco M, Mingrone G. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. Diabetologia. 2008 Jul;51(7):1276-84. doi: 10.1007/s00125-008-1007-y. Epub 2008 May 6.

    PubMed 18458872
  • Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):574-9. doi: 10.1016/j.numecd.2008.07.004.

    PubMed 18790374
  • Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009 Mar;32(3):514-20. doi: 10.2337/dc08-1762. No abstract available.

    PubMed 19246589
  • Mingrone G, Castagneto M. Bariatric surgery: unstressing or boosting the beta-cell? Diabetes Obes Metab. 2009 Nov;11 Suppl 4:130-42. doi: 10.1111/j.1463-1326.2009.01120.x.

    PubMed 19817795
  • Gastaldelli A, Iaconelli A, Gaggini M, Magnone MC, Veneziani A, Rubino F, Mingrone G. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. Diabetes Care. 2016 Nov;39(11):1925-1931. doi: 10.2337/dc15-2823. Epub 2016 Aug 29.

    PubMed 27573937

Questions about this trial

What is this clinical trial studying?

An observational study of Morbid Obesity, run by Catholic University of the Sacred Heart at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Insulin sensibility pre and post bariatric surgery with euglycaemic hyperinsulinemic clamp (EHC) (time frame: 12 and 11 weeks before surgery and 1 week after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01063127, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in